Fate Therapeutics Inc stock is traded at $1.61, with a volume of 2,650,080. It is down -9.32% in the last 24 hours and down -24.65% over the past month. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Previous Close:
$1.77
Open:
$1.78
24h Volume:
2,650,080
Relative Volume:
1.65
Market Cap:
$195.12M
Revenue:
$6.65M
Net Income/Loss:
-$136.32M
P/E Ratio:
-
EPS:
-$1.15
Net Cash Flow:
-$112.04M
1W Performance:
-13.24%
1M Performance:
-24.65%
6M Performance:
-28.67%
1Y Performance:
+54.33%
1-Day Range:
$1.60$1.80
1-Week Range:
$1.60$2.00
52-Week Range:
$0.95$3.23
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
858.875.1803Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS